Log In
Print this Print this

pradigastat (LCQ908)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionDiacylglycerol O-acyltransferase-1 (DGAT1) inhibitor
Molecular Target Diacylglycerol O-acyltransferase-1 (DGAT1)
Mechanism of ActionDiacylglycerol O-acyltransferase-1 (DGAT1) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard Indication Metabolic (unspecified)
Indication DetailsTreat familial chylomicronemia syndrome (FCS) (HLP Type I); Treat metabolic diseases; Treat non familial chylomicronemia syndrome (Non-FCS)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today